[1]伍雯莹a,黄娅芬b,梅 巧c.子宫内膜癌组织中IGF2BP1mRNA，PEG10mRNA 表达及与增殖基因表达的相关性和预后研究[J].现代检验医学杂志,2024,39(04):16-22.[doi:10.3969/j.issn.1671-7414.2024.04.004]
　WU Wenyinga,HUANG Yafenb,MEI Qiaoc.Expression of IGF2BP1 mRNA and PEG10 mRNA in Endometrial Carcinoma and Their correlation with Proliferation Gene Expression and Prognosis[J].Journal of Modern Laboratory Medicine,2024,39(04):16-22.[doi:10.3969/j.issn.1671-7414.2024.04.004]
点击复制

子宫内膜癌组织中IGF2BP1mRNA，PEG10mRNA 表达及与增殖基因表达的相关性和预后研究()
分享到：

《现代检验医学杂志》[ISSN:/CN:]

卷:
第39卷
期数:
2024年04期
页码:
16-22
栏目:
论著
出版日期:
2024-07-15

文章信息/Info

Title:
Expression of IGF2BP1 mRNA and PEG10 mRNA in Endometrial Carcinoma and Their correlation with Proliferation Gene Expression and Prognosis
文章编号:
1671-7414（2024）04-016-07
作者:
伍雯莹a; 黄娅芬b; 梅 巧c
[黄石市妇幼保健院（湖北理工学院附属妇幼保健院）a. 妇女保健科；b. 妇科；c. 中医妇科，湖北黄石 435000]
Author(s):
WU Wenyinga;  HUANG Yafenb;  MEI Qiaoc
[a. Department of Women’s Health Care; b. Department of Gynaecology; c. Department of TCM Gynaecology, Huangshi Maternity of Children’s Health Hospital（Affiliated Maternity and Children’s Health Hospital of Hubei Polytechnic University）, Hubei Huangshi 435000, China)
关键词:
子宫内膜癌; 胰岛素样生长因子2 mRNA 结合蛋白1; 父系表达遗传印记基因10; 增殖; 临床病理特征
分类号:
R737.33；R730.43
DOI:
10.3969/j.issn.1671-7414.2024.04.004
文献标志码:
A
摘要:
目的 研究子宫内膜癌（endometrial carcinoma，EC）组织中胰岛素样生长因子2 mRNA 结合蛋白1（insulinlikegrowth factor 2 mRNA binding protein 1，IGF2BP1）mRNA，父系表达遗传印记基因10（patrilineal expression ofgenetic imprinting gene 10，PEG10）mRNA 表达及与增殖基因表达的相关性及预后。方法 选取2017 年1 月~2019 年1 月湖北理工学院附属妇幼保健院诊治的100 例EC 患者。实时荧光定量PCR 检测EC 癌组织和癌旁组织中IGF2BP1mRNA，PEG10 mRNA 及增殖细胞核抗原（proliferating cell nuclear antigen，PCNA）mRNA，细胞周期素D1(cyclinD1) mRNA，细胞周期蛋白依赖激酶4（cyclin dependent kinase 4，CDK4）mRNA 表达。免疫组织化学检测IGF2BP1，PEG10 蛋白表达。相关性采用Pearson 相关分析。Kaplan-Meier 曲线分析不同IGF2BP1，PEG10 表达组EC 患者的预后差异。COX 回归分析EC 患者的预后影响因素。结果 EC 癌组织中IGF2BP1 mRNA（1.84±0.33），PEG10 mRNA（2.12±0.40），PCNA mRNA（3.14±0.42），cyclinD1 mRNA（2.81±0.36），CDK4 mRNA（2.37±0.34）高于癌旁组织（0.78±0.21，0.91±0.25，0.74±0.13，0.67±0.21，0.59±0.18）， 差异具有统计学意义（t=25.652 ～ 54.588，均P<0.05）。癌组织中IGF2BP1（70.00%），PEG10（72.00%）蛋白阳性率高于癌旁组织（100%，9.00%），差异具有统计学意义（χ2=75.000，82.363，均P ＜ 0.05）。EC 中IGF2BP1 mRNA，PEG10 mRNA 表达与PCNA mRNA，cyclinD1 mRNA，CDK4 mRNA 表达呈正相关（r=0.562 ～ 0.625， 均P<0.05）。EC 中IGF2BP1 mRNA 与PEG10mRNA 表达呈显著正相关（r=0.663，P<0.05）。FIGO 分期Ⅲ期、并发淋巴结转移EC 癌组织中IGF2BP1（86.49%，87.50%），PEG10（89.19%，90.63% ）阳性率高于FIGO 分期Ⅰ～Ⅱ期（60.32%，61.90%）、无淋巴结转移（61.77%，63.24%），差异具有统计学意义（χ2=6.863 ～ 8.608，均P<0.05）。IGF2BP1 阳性组患者三年总体生存率70.00%（49/70）低于阴性组的90.00%（27/30）；PEG10 阳性组患者三年总体生存率为69.44%（50/72）, 低于阴性组的92.86%（26/28），差异具有统计学意义（Log-rank χ2=4.133，5.491，P=0.042，0.019）。FIGO 分期Ⅲ期（OR=1.449，95%CI：1.148~1.830）、并发淋巴结转移（OR=1.442，95%CI:1.124~1.850），IGF2BP1 阳性（OR=1.637，95%CI:1.239~2.163）及PEG10 阳性（OR=1.576，95%CI:1.136~1.187）是影响EC 患者生存预后的独立危险因素（均P<0.05）。结论 EC 中IGF2BP1，PEG10 表达升高，两者与增殖基因表达呈正相关，是EC 预后评估的肿瘤标志物。
Abstract:
Objective To investigate the expression of insulin-like growth factor 2 mRNA binding protein 1 (IGF2BP1) mRNA and patrilineal expression of genetic imprinting gene 10 (PEG10) mRNA in endometrial carcinoma (EC) tissues and their correlation with proliferation gene expression and prognosis. Methods A total of 100 EC patients diagnosed and treated in Hubei Institute of Technology Affiliated Maternal and Child Health Hospital from January 2017 to January 2019 were selected. The expression of IGF2BP1 mRNA, PEG10 mRNA, proliferating cell nuclear antigen (PCNA), cyclin D1, and cyclin dependent kinase 4 (CDK4) mRNA were examined by real-time fluorescence quantitative PCR. The expressions of IGF2BP1 and PEG10 in tissues were detected by immunochemistry, and their correlation were analyzed by Pearson correlation analysis. Kaplan-Meier curve analysis were used to analyze the prognostic differences in EC patients with different IGF2BP1 and PEG10 expression groups. COX regression was used to analyze the prognostic factors of EC patients. Results The expression levels of IGF2BP1 mRNA (1.84±0.33), PEG10 mRNA (2.12±0.40), PCNA mRNA(3.14±0.42), cyclinD1 mRNA(2.81±0.36) and CDK4 mRNA(2.37±0.34) in EC cancer tissues were higher than those in adjacent tissues(0.78±0.21, 0.91±0.25, 0.74±0.13, 0.67±0.21, 0.59±0.18), and the differences were significant (t=25.652 ～ 54.588, all P<0.05). The positive rates of IGF2BP1 (70.00%) and PEG10 (72.00%) in cancer tissues were higher than those in adjacent tissues (10.00%, 9.00%), and the differences were statistically significant(χ2=75.000, 82.363, all P<0.05). The expressions of IGF2BP1 mRNA and PEG10 mRNA in EC tissues were positively correlated with PCNA mRNA, cyclinD1 mRNA, and CDK4 mRNA (r=0.562 ～ 0.625, all P<0.05). There was a significant positive correlation between IGF2BP1 mRNA and PEG10 mRNA expression in EC tissues (r=0.663, P<0.05). The positive rates of IGF2BP1 (86.49%, 87.50%) and PEG10 (89.19%, 90.63%) protein expression in EC cancer tissues with FIGO stage III and combined lymph node metastasis were higher than those in FIGO stage I-II(60.321%, 61.90%) and without lymph node metastasis (61.77%, 63.24%), and the differences were sttistically significant(χ2=6.863~8.608, all P<0.05). The overall 3-year survival rate of IGF2BP1 positive patients[70.00%(49/70)] was lower than that of IGF2BP1 negative patients [90.00%(27/30)], the overall 3-year survival rate of patients in PEG10 positive patients [69.40(50/72)] was lower than that in PEG10 negative patients [92.86% (26/28)], and the differences were statistically significant (Log rankχ2=4.133, 5.491, P=0.042, 0.019). FIGO stage III (OR=1.449, 95%CI: 1.148~1.830), combined lymph node metastasis (OR=1.442, 95%CI:1.124~1.850), IGF2BP1 positive (OR=1.637, 95%CI: 1.239~2.163), and PEG10 positive (OR=1.576, 95%CI: 1.136~1.187) were independent risk factors affecting the survival and prognosis of EC patients (all P<0.05). Conclusion The expressions of IGF2BP1 and PEG10 in EC were increased, and they were positively correlated with the proliferation gene expression. They may be potential tumor markers for prognostic evaluation of EC.

参考文献/References:

[1] SUNDSTROM K, ELFSTROM K M. Advances in cervical cancer prevention: efficacy, effectiveness, elimination?[J].PLoS Medicine, 2020, 17(1): e1003035.
[2] 陈丽华, 朱婕曼, 刘玉凤, 等. 子宫内膜癌组织中血管紧张素(1-7) 及线粒体组装受体水平表达与临床病理特征的相关性[J]. 现代检验医学杂志, 2021,36(2)：24-27. CHEN Lihua, ZHU Jieman, LIU Yufeng, et al. Correlation between the expression of angiotensin (1-7) and mitochondrial assembled receptors and clinicopathological characteristics in endometrial cancer[J]. Journal of Modern Laboratory Medicine, 2021, 36(2): 24-27.
[3] MU Hongbei, CAI Siying, WANG Xiaofei, et al. Corrigendum to RNA binding protein IGF2BP1 meditates oxidative stress-induced granulosa cell dysfunction by regulating MDM2 mRNA stability in an m6A-dependent manner[Redox Biol.57(2022)102492/102492] [J]. Redox Biology, 2023.67: 102880.
[4] BLEY N, SCHOTT A, M?LLER S, et al. IGF2BP1 is a targetable SRC/MAPK-dependent driver of invasive growth in ovarian cancer[J]. RNA Biology, 2021, 18(3): 391-403.
[5] SHI Hongying, SHI Caixia, YAN Zhipeng, et al. LRRC75A-AS1 drives the epithelial-mesenchymal transition in cervical cancer by binding IGF2BP1 and inhibiting SYVN1-mediated NLRP3 ubiquitination[J]. Molecular Cancer Research, 2024. DOI: 10.1158/1541-7786. MCR-23-0478. Epub ahead of print. PMID: 38180377.
[6] BLACK H H, HANSON J L, ROBERTS J E, et al. UBQLN2 restrains the domesticated retrotransposon PEG10 to maintain neuronal health in ALS[J]. eLife, 2023, 12: e79452.
[7] KAWAI Y, IMADA K, AKAMATSU S, et al. Paternally expressed gene 10 (PEG10) promotes growth, invasion, and survival of bladder cancer[J]. Molecular Cancer Therapeutics, 2020, 19(10): 2210-2220.
[8] YOSHIDA A, PHILLIPS-MASON P, TARALLO V, et al. Non-phosphorylatable cyclin D1 mutant potentiates endometrial hyperplasia and drives carcinoma with Pten loss[J]. Oncogene, 2022, 41(15): 2187-2195.
[9] 张秀俊, 陈玉芬, 朱芳, 等. miR-25-3p 靶向调节PTEN 对子宫内膜癌细胞增殖、凋亡和迁移侵袭的影响[J]. 中国优生与遗传杂志, 2022, 30(11): 1920-1926. ZHANG Xiujun, CHEN Yufen, ZHU Fang, et al. The impacts of miR-25-3p on the proliferation, apoptosis, migration and invasion of endometrial cancer cells by targeting and regulating PTEN[J]. Chinese Journal of Birth Health & Heredity, 2022, 30(11): 1920-1926.
[10] SOSLOW R A, TORNOS C, PARK K J, et al. Endometrial carcinoma diagnosis: use of FIGO grading and genomic subcategories in clinical practice: recommendations of the international society of gynecological pathologists[J]. International Journal of Gynecological Pathology, 2019, 38 Suppl 1 (Iss 1 Suppl 1): S64-S74.
[11] SIEGEL R L, MILLER K D, FUCHS H E, et al. Cancer statistics, 2022[J]. CA: A Cancer Journal for Clinicians, 2022, 72(1): 7-33.
[12] S?L?NOU C, BRIOUDE F, GIABICANI E, et al. IGF2: development, genetic and epigenetic abnormalities[J]. Cells, 2022, 11(12): 1886.
[13] HUANG Huilin, WENG Hengyou, SUN Wenju, et al. Recognition of RNA N6-methyladenosine by IGF2BP proteins enhances mRNA stability and translation[J]. Nature Cell Biology, 2018, 20(3): 285-295.
[14] HUANG Xinwei, ZHANG Hong, GUO Xiaoran, et al. Insulin-like growth factor 2 mRNA-binding protein 1 (IGF2BP1) in cancer[J]. Journal of Hematology & Oncology, 2018, 11(1): 88.
[15] SHI Wenjing, TANG Yongzhe, LU Jing, et al. MIR210HG promotes breast cancer progression by IGF2BP1 mediated m6A modification[J]. Cell and Bioscience, 2022, 12(1): 38.
[16] XUE Teng, LIU Xiaoqiu, ZHANG Mei, et al. PADI2-catalyzed MEK1 citrullination activates ERK1/2 and promotes IGF2BP1-mediated SOX2 mRNA stability in endometrial cancer[J]. Advanced Science (Weinheim, Baden-Wurttemberg, Germany), 2021, 8(6): 2002831.
[17] M?LLER S, BLEY N, BUSCH B, et al. The oncofetal RNA-binding protein IGF2BP1 is a druggable, posttranscriptional super-enhancer of E2F-driven gene expression in cancer[J]. Nucleic Acids Research, 2020, 48(15): 8576-8590.
[18] LI Na, ZHAN Xianquan. Identification of pathologyspecific regulators of m 6 A RNA modification to optimize lung cancer management in the context of predictive, preventive, and personalized medicine[J]. EPMA Journal, 2020, 11(3): 485-504.
[19] LAN Q, LIU P Y, BELL J L, et al. The emerging roles of RNA m6A methylation and demethylation as critical regulators of tumorigenesis,drug sensitivity,and resistance[J]. Cancer Research, 2021, 81(13): 3431-3440.
[20] XI Yufeng, WANG Yujia. IGF2BP1, a new target to overcome drug resistance in melanoma?[J]. Frontiers in Pharmacology, 2022, 13: 947363.
[21] ZHANG Bin, LIU Zhiyi, WU Rui, et al. Transcriptional regulator CTR9 promotes hepatocellular carcinoma progression and metastasis via increasing PEG10 transcriptional activity[J]. Acta Pharmacologica Sinica, 2022, 43(8): 2109-2118.
[22] TANG F H, CHANG WA TSAI E M, et al. Investigating novel genes potentially involved in endometrial adenocarcinoma using next-generation sequencing and bioinformatic approaches[J]. International Journal of Medical Sciences, 2019, 16(10): 1338-1348.
[23] YE Mengling, ZHAO Lu, ZHANG Lu, et al. LncRNA NALT1 promotes colorectal cancer progression via targeting PEG10 by sponging microRNA-574-5p[J]. Cell Death & Disease, 2022, 13(11): 960.
[24] SINHA A, ZOU Yong, PATEL A S, et al. Early-stage lung adenocarcinoma MDM2 genomic amplification predicts clinical outcome and response to targeted therapy[J]. Cancers, 2022, 14(3): 708.
[25] ZHANG Lin, WAN Yicong, ZHANG Zihan, et al. IGF2BP1 overexpression stabilizes PEG10 mRNA in an m6A-dependent manner and promotes endometrial cancer progression[J]. Theranostics, 2021, 11(3): 1100-1114.

相似文献/References:

[1]李 玲a,罗雅文a,何 霞a,等.子宫内膜癌患者BMI与血清HE4,CA125联合检测的诊断价值[J].现代检验医学杂志,2018,33(05):91.[doi:10.3969/j.issn.1671-7414.2018.05.024]
　LI Linga,LUO Ya-wena,HE Xiaa,et al.Diagnostic Value of Combined Detection of Body Mass Index and Serum HE4,CA125 in Patients with Endometrial Carcinoma[J].Journal of Modern Laboratory Medicine,2018,33(04):91.[doi:10.3969/j.issn.1671-7414.2018.05.024]
[2]李晓丽,胡陇娟.子宫内膜癌组织中长链非编码RNA ZEB1-AS1的表达与临床特征及对化疗药物耐药性研究[J].现代检验医学杂志,2019,34(04):35.[doi:10.3969/j.issn.1671-7414.2019.04.009]
　LI Xiao-li,HU Long-juan.Research on Expression and Clinical Characteristics of Long-Chain Non-Coding RNA ZEB1-AS1 in Endometrial Carcinoma and Resistance to Chemotherapy Drugs[J].Journal of Modern Laboratory Medicine,2019,34(04):35.[doi:10.3969/j.issn.1671-7414.2019.04.009]
[3]王娟,刘鑫,席稳燕.HMMR-AS1 在子宫内膜癌化疗耐药中的作用[J].现代检验医学杂志,2020,35(05):45.[doi:10.3969/j.issn.1671-7414.2020.05.012]
　WANG Juan,LIU Xin,XI Wen-yan.Effect of HMMR-AS1 on the Chemotherapy-Resistance of Endometrial Cancer[J].Journal of Modern Laboratory Medicine,2020,35(04):45.[doi:10.3969/j.issn.1671-7414.2020.05.012]
[4]李功娟,张治洋,樊阳阳.FEZF1-AS1在子宫内膜癌中的表达及其与患者临床特征的相关性[J].现代检验医学杂志,2021,36(01):77.[doi:10.3969/j.issn.1671-7414.2021.01.020]
　LI Gong-juan,ZHANG Zhi-yang,FAN Yang-yang.Expression of FEZF1-AS1 in Endometrial Carcinoma and Its Correlation with Clinical Characteristics of Patients[J].Journal of Modern Laboratory Medicine,2021,36(04):77.[doi:10.3969/j.issn.1671-7414.2021.01.020]
[5]陈丽华,朱婕曼,刘玉凤,等.子宫内膜癌组织中血管紧张素~1-7及线粒体组装受体水平表达与临床病理特征的相关性[J].现代检验医学杂志,2021,36(02):24.[doi:doi:10.3969/j.issn.1671-7414.2021.02.006]
　CHEN Li-hua,ZHU Jie-man,LIU Yu-feng,et al.Correlation between the Expression of Angiotensin (1-7) and Mitochondrial Assembled Receptors and Clinicopathological Characteristics in Endometrial Cancer[J].Journal of Modern Laboratory Medicine,2021,36(04):24.[doi:doi:10.3969/j.issn.1671-7414.2021.02.006]
[6]陈晓宇,曾庆维,陈红林,等.子宫内膜癌组织中miR-3188和mTOR表达量与预后的相关性研究[J].现代检验医学杂志,2021,36(06):17.[doi:10.3969/j.issn.1671-7414.2021.06.004]
　CHEN Xiao-yu,ZENG Qing-wei,CHEN Hong-lin,et al.Study on the Correlation between the Expression Levels of miR-3188 and mTOR in Endometrial Cancer and the Prognosis[J].Journal of Modern Laboratory Medicine,2021,36(04):17.[doi:10.3969/j.issn.1671-7414.2021.06.004]
[7]刘静雅,张海亮,李宝平,等.长链非编码 RNA SNHG1在子宫内膜癌中的表达及调控 PI3K/AKT信号通路的研究[J].现代检验医学杂志,2022,37(01):119.[doi:10.3969/j.issn.1671-7414.2022.01.024]
　LIU Jing-ya,ZHANG Hai-liang,LI Bao-ping,et al.Expression of Long Non-coding RNA SNHG1 in Endometrial Carcinoma and Its Regulation of PI3K/AKT Signaling Pathway[J].Journal of Modern Laboratory Medicine,2022,37(04):119.[doi:10.3969/j.issn.1671-7414.2022.01.024]
[8]彭 浩,张印星,谢 环.长链非编码RNA CDKN2BAS 在子宫内膜癌组织表达及其生物学功能研究[J].现代检验医学杂志,2023,38(03):92.[doi:10.3969/j.issn.1671-7414.2023.03.016]
　PENG Hao,ZHANG Yin-xing,XIE Huan.Expression and Biological Function of Long Non-coding RNA CDKN2BAS in Endometrial Carcinoma[J].Journal of Modern Laboratory Medicine,2023,38(04):92.[doi:10.3969/j.issn.1671-7414.2023.03.016]
[9]梁燕茹,郑 瑜,李 倩.子宫内膜癌患者术前血清apo AI 和Apelin 水平检测对预测淋巴脉管间隙浸润风险的价值研究[J].现代检验医学杂志,2023,38(05):53.[doi:10.3969/j.issn.1671-7414.2023.05.010]
　LIANG Yanru,ZHENG Yu,LI Qian.Value of Preoperative Serum Apo AI and Apelin Levels in Predicting the Risk of Lymph Node Vascular Space Infiltration in Patients with Endometrial Cancer[J].Journal of Modern Laboratory Medicine,2023,38(04):53.[doi:10.3969/j.issn.1671-7414.2023.05.010]
[10]陆 瑞,郭红霞,吴苗苗,等.KIF18B 通过激活Wnt/β catenin 信号通路促进子宫内膜癌细胞增殖和转移的实验研究[J].现代检验医学杂志,2023,38(05):58.[doi:10.3969/j.issn.1671-7414.2023.05.011]
　LU Rui,GUO Hongxia,WU Miaomiao,et al.Experimental Study of KIF18B Promoting Endometrial Cancer Cell Proliferation and Metastasis by Activating Wnt/β-catenin Signaling Pathway[J].Journal of Modern Laboratory Medicine,2023,38(04):58.[doi:10.3969/j.issn.1671-7414.2023.05.011]

备注/Memo

备注/Memo:
基金项目：湖北省卫生健康委第三批联合基金项目（编号：WJ2019H480）。
作者简介：伍雯莹（1985-），女，硕士，主治医师，研究方向: 妇科肿瘤，E-mail：wuwenweny1985@163.com。
通讯作者：梅巧（1989-），女，硕士，主治医师，研究方向：中西医结合治疗妇科疾病，E-mail：2598626589@qq.com。
更新日期/Last Update: 2024-07-15